Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 2/20 | 0.53 |
| ▸ | CDK9 | P50750 | 2/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.46 |
| ▸ | MET | P08581 | 6/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690353 | 0.94 | CDK7 (0.53) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL31251255 | 0.89 | CDK7 (0.52) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL32690298 | 0.88 | CDK7 (0.52) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL32690426 | 0.88 | CDK7 (0.55) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL32690311 | 0.85 | CDK7 (0.54) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL32690290 | 0.85 | PTK2 (0.57) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL31251379 | 0.84 | CDK7 (0.52) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL32690417 | 0.84 | CDK7 (0.51) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL31251139 | 0.82 | CDK7 (0.53) | CDK7CDK9ALKPTK2MET | |
| SCHEMBL31251107 | 0.80 | CDK7 (0.58) | CDK7CDK9ALKPTK2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | CDK7 159/4885CDK9 96/4885ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.